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Abstract Research on the role of digestion in overall
health has driven increasing interest in the use of digestive
enzymes, which may improve nutrient absorption and
reduce gastrointestinal symptoms. Sales of digestive aids
and enzymes have grown over 8% in 2009, with enzymes
accounting for $69 million of this growing category. Recent
clinical research reported that acute dosing of Aminogen®,
a patented blend of digestive protease enzymes isolated
from Aspergillus and blended with whey protein concen-
trate, increased the rate of protein absorption. The results
indicated a faster rate of amino acid absorption reflected in
significantly higher blood levels of amino acids, increased
nitrogen retention, and significantly reduced levels of
C-reactive protein. Few studies, however, have examined
the safety of repeated dosing of oral enzymes with an
appropriate substrate. The purpose of this study, therefore,
was to evaluate basic measures of clinical safety during
30 days of continuous, repeated dosing of Aminogen® and
whey protein supplementation in healthy, active men
maintaining a regimen of resistance training. Parameters
evaluated include various markers of general physical
health, metabolic function, hepato-renal function, and
cardiovascular health including fasting blood lipids. Forty
healthy, resistance-trained men (27.1±7.9 years) were
recruited for this double-blind, randomized study. Group
A ingested two 40-g doses of whey protein per day
containing Aminogen®. Group B ingested two 40-g doses
of whey protein per day. No significant changes were
noted in measures of general physical health, metabolic
function, cardiovascular health, and hepato-renal func-
tion within or between groups. However, total choles-
terol, LDL cholesterol, and serum calcium significantly
increased (P<0.05) in group B. In group A, whey protein
containing Aminogen® was well tolerated with no adverse
reactions reported. No differences in serum markers of
clinical safety and an improved blood lipid profile are
also reported.
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Introduction
Research on the importance of digestion for overall health
has driven increasing interest in the use of digestive
enzymes, which may improve nutrient absorption and
reduce gastrointestinal symptoms [1]. Sales of digestive
aids and enzymes have grown over 8% in the last year, with
enzymes accounting for $69 million of this growing
category [2]. Although supplementing with digestive
enzymes is becoming increasingly popular, there is little
clinical data available regarding the safety of oral fungal
proteases as digestive aids or dietary supplements. This
may be due in part to confusion regarding effective dose
and activity, which is substrate specific and temperature
sensitive, after oral dosing. Digestive enzyme supplemen-
tation may also simply be presumed to be safe, since
enzymes have been used in food processing and as food
additives for almost a century. The heat generated in food
processing and cooking typically destroys enzyme activity
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before ingestion [3]. Conversely, activity of enzymes for
dietary supplementation should be intact to aid in digestion
when taken orally. Recent clinical research has shown that
Aminogen®, a patented oral fungal protease blend, main-
tains activity after oral dosing. Acute dosing of Aminogen®
with whey protein concentrate was effective for increasing
the rate of protein absorption [4]. Forty healthy males were
divided into two groups and received either 50 g whey
protein concentrate (80% protein) or 50 g of whey protein
concentrate with Aminogen®. The results indicated a faster
rate of amino acid absorption reflected in significantly
higher blood levels of amino acids and increased nitrogen
retention in the Aminogen® group; significant reductions in
C-reactive protein levels were also reported. However, no
data have been reported regarding the basic clinical safety
from repeated oral dosing of the protease blend with an
appropriate substrate. The purpose of this study, therefore,
was to evaluate basic measures of clinical safety after
combining Aminogen® and whey protein supplementation
for 30 days of continuous dosing in healthy, active men
maintaining a regimen of resistance training. Parameters
evaluated include changes in various markers of general
physical health, metabolic function, hepato-renal function,
and cardiovascular health including fasting blood lipids. It
is hypothesized that the addition of Aminogen® to whey
protein will be well tolerated as indicated by compliance,
absence of adverse events, non-significant changes in
hemodynamic parameters, and normal ranges of all clinical




This investigation was conducted in compliance with Good
Clinical Practices, approved by an Institutional Review
Board, and required the recruitment of two groups of
healthy, male subjects. Following a 10-h fast, participants
were assessed for resting heart rate, blood pressure weight
and body mass index. Participants then donated a fasting
blood sample for standard serum clinical chemistry analy-
ses. Upon completing baseline testing, participants were
assigned in a double-blind fashion to one of two treatment
groups. After completing 4 weeks of a resistance training
program, participants returned for a post-testing session
identical to their baseline testing session. Body weight and
hemodynamic and clinical chemistry data were statistically
evaluated for significant differences at a significance level
of 0.05. Subjects with incomplete data sets would be
dropped, and no incomplete data sets were used for
statistical analyses.
Subjects
A priori power analysis for this design was done based on
detecting 1-kg lean mass change (delta) between groups. At a
5% level of significance, a sample size of 20 subjects per group
yields an acceptable power (>0.75) for delta values of 0.75 to
1.25. Forty healthy men between the ages of 18 and 45 years
were recruited and randomized into two parallel groups (A &
B) of 20 subjects each and matched according to age, weight,
body mass index, and exercise background. Twenty partic-
ipants completed the study in group A, and 16 participants
completed the study in group B. Data for the 36 participants
that completed the study were used for all statistical analyses
including baseline total mean data (Table 1). Inclusion criteria
for all participants required them to: (1) be in good health
according to health history questionnaire and routine blood
chemistries; (2) have a body mass index of 20-35. (3) have
been resistance training regularly (defined as completing
three workouts per week on average) for at least 2 years
according to completed physical activity questionnaire; (4) be
willing and able to comply with the supplement and training
protocol; and (5) have reviewed, signed, and dated the
informed consent forms provided by the investigator to
participate in the study. This subject profile was selected
since Aminogen® has gained popularity in the sports
nutrition industry.
Participants were excluded if they: (1) were currently
participating or had participated in other research studies
within the last 30 days; (2) had gained or lost more than 10 lb
in the last 30 days; (3) did not verbally express comprehension
of the informed consent document; (4) reported past or current
use of anabolic steroids, IGF-1, growth hormone, or any other
anabolic drugs within the past year, as well as patients who
had taken thyroid, hyperlipidemic, hypoglycemic, anti-
hypertensive, anti-coagulant, or androgenic medications; (5)
reported having taken or were currently taking ergogenic
levels of nutritional supplements that may affect muscle mass
(e.g., creatine, HMB) or anabolic/catabolic hormone levels
(androstenedione, DHEA, etc.) within 6 weeks prior to the
start of the study; and (6) reported to have a known allergy to
any ingredients in Aminogen® or whey protein. Finally,
participants were excluded if they were receiving medical
treatment including: (but not limited to) receiving prescription
medications for or being diagnosed with any form of
pulmonary, metabolic, psychiatric, neuromuscular, orthope-
dic, or cardiovascular condition which may alter their normal
physiological adaptation to nutritional supplementation and
resistance training.
Familiarization Session
All participants were familiarized with the study procedures
and assessed for baseline height and weight after submitting
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a completed, signed Informed Consent Agreement. Stand-
ing height was measured by a wall-mounted stadiometer
while body mass was assessed using SECA 767 Medical
scale (±0.1 kg). All participants met with the study dietitian,
who provided education and background on how to
properly complete a 3-day food intake record based on
household measures. The initial baseline testing session
was scheduled no less than 4 days and typically no more
than 2 weeks after completion of familiarization.
Procedures
Participants were instructed to avoid heavy exercise for the
48 h prior to their scheduled initial testing session.
Participants also completed a food intake record consisting
of all food and fluid intake over a 3-day period consisting
of at least two weekdays and one weekend day. All baseline
food intake data were entered into Nutribase IV Nutrition
Software, CyberSoft, Inc. (Phoenix, AZ) and analyzed for
average energy and macronutrient intake by the study
dietitian. Participants were instructed to maintain consistent
eating habits relative to energy and macronutrient intake
throughout the study. Additional 3-day diet records were
analyzed by the study dietitian at week 2 and during post-
testing (week 4) to verify that eating habits remained
consistent throughout the study. No assessment was made
for over- or underreporting.
Upon arrival and at all testing sessions, heart rate was
determined by palpation of the radial artery, and blood
pressure was taken with an automated sphygmomanometer
(LifeSource UA-851V). Body weight was determined using
a SECA 767 Medical scale (±0.1 kg).
Prior to arriving for all testing sessions, participants were
asked to observe a 10-h fast (no eating of any food or
drinking of any fluid with calories). To control for any
diurnal variations in blood markers, all testing sessions
Table 1 Baseline (T0) anthropometric, body composition, biochemical parameters, and dietary analysis for the Aminogen®+whey protein (group
A) and whey protein (group B) subject groups
Demographics Total mean (n=36) Group A (n=20) Group B (n=16) p value
Age (years) 27.1±7.9 27.8±8.2 26.4±7.6 0.61
Height (cm) 179±6 178±5 179±6 0.58
Weight (kg) 82.2±10.8 82.0±7.6 82.4±14.1 0.91
Body mass index (kg m−2) 25.7±2.6 25.8±1.9 25.5±3.4 0.78
Resting heart rate (bpm) 69.5±9.3 69.8±10.0 69.1±8.7 0.83
Systolic blood pressure (mmHg) 121.3±11.6 123.7±11.5 118.4±11.3 0.17
Diastolic blood pressure (mmHg) 75.7±8.6 78.9±7.9a 71.8±7.9 0.01
Biochemical parameters Total Mean (n=36) Group A (n=20) Group B (n=16) p value
Total cholesterol (mmol L−1) 3.9±0.9 4.1±0.8 3.7±0.9 0.10
HDL cholesterol (mmol L−1) 1.3±0.5 1.2±0.4 1.4±0.7 0.37
LDL cholesterol (mmol L−1) 2.3±0.8 2.5±0.8 2.1±0.8 0.15
Triglycerides (mmol L−1) 0.84±0.36 0.9±0.5 0.76±0.20 0.21
Glucose (mmol L−1) 4.9±0.4 5.0±0.4a 4.7±0.3 0.006
Potassium (U L−1) 4.27±0.29 4.33±0.33 4.19±0.22 0.16
Calcium (mg dL−1) 9.5±0.27 9.6±0.24 9.4±0.31 0.23
Alkaline phosphatase (U L−1) 69.0±15.0 71.3±15.8 66.3±14.0 0.33
AST (IU L−1) 28.9±17.8 33.1±22.1 23.6±8.1 0.11
ALT (IU L−1) 28.9±21.6 35.7±26.5a 20.3±7.7 0.03
BUN (mg dL−1) 17.6±4.5 17.7±4.92 17.6±3.98 0.99
Creatinine (mg dL−1) 1.80±4.47 2.32±5.2 1.15±0.17 0.37
BUN/creatinine 15.2±3.3 15.1±3.7 15.4±2.8 0.76
Total protein (U L−1) 7.1±0.39 7.1±0.42 7.0±0.36 0.73
Dietary intake Total mean (n=36) Group A (n=20) Group B (n=16) p value
Caloric intake (kcal/day) 2,662±670 2,609±581 2,729±782 0.60
Caloric intake (kcal/kg/day) 32.7±8.2 32.1±7.9 33.4±8.7 0.63
Carbohydrate (g/kg/day) 3.3±1.0 3.2±1.1 3.4±0.9 0.47
Protein (g/kg/day) 2.9±1.0 2.8±0.7 3.0±1.3 0.64
Fat (g/kg/day) 0.9±0.3 0.92±0.3 0.88±0.4 0.74
All data are presented as means±SD at baseline. Significance level was set at 0.05
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were scheduled at similar times. A fasting blood sample
(∼15 mL) was collected from an antecubital vein into serum
separation tubes (Vacutainer™ Becton Dickson) using
standard phlebotomy techniques. All blood samples were
centrifuged (3,000×g) for 10 min using a standard benchtop
centrifuge; serum was sent to Quest Diagnostics Laboratory
(Pittsburgh, PA) for lipid and metabolic automated chem-
istry profiles. Lipid profile included: total cholesterol, LDL
cholesterol, HDL cholesterol, and total cholesterol/HDL
and triglycerides. Metabolic profile included: sodium,
potassium, chloride, carbon dioxide, calcium, albumin,
bilirubin, globulin, albumin/globulin, alkaline phosphatase,
glucose, blood urea nitrogen (BUN), creatinine, BUN/
creatinine, total protein, glomerular filtration rate, kidney
and liver enzymes (aspartate aminotransferase, alanine
aminotransferase).
Supplementation Protocol
Single doses of either (a) whey protein concentrate, blended
with 3% Aminogen® (Triarco Industries, Wayne, NJ) and
0.2% Natural Vanilla (Craftmaster) or (b) 50 g whey protein
concentrate blended with 0.2% Natural Vanilla was pre-
packaged, stamped with either an A or a B and shipped to
the facilities of Applied Health Sciences clinical research
organization (Fairlawn, OH) where the study was con-
ducted. No solubilizers, emulsifiers, or other excipients
were added to the protein concentrate. The contents of the
packets were blinded to the testing facility staff as well as
the subjects. Subjects were matched into parallel groups
according to body mass index, weight, age, and resistance
experience. They were then randomly assigned to ingest
either packet A or packet B twice a day for the duration of
the study. One packet was taken 30 min before resistance
training, and another one was taken immediately after. On
non-training days, both groups ingested their respective
packets at breakfast and before bed. All packets were
prepared by mixing the entire contents with 8–10 oz of
water. The whey protein for both groups was Avonlac 180
(Glanbia Nutritionals, Twin Falls, ID) consisting of 80%
protein, less than 10% fat, less than 5% moisture, less than
5% minerals, and 5% lactose. Consumption was matched
for total caloric content and ingested at the same time of
day during the study. Subjects were contacted by a study
dietician weekly to monitor compliance with the supple-
mentation protocol and complete a questionnaire (by
phone) to monitor changes in appetite, stomach distress,
sleep habits, muscle soreness and cramping, irritability,
headache, general attitude, appetite, and any other idiosyn-
cratic responses to the supplementation and training
protocol. In addition to the weekly phone calls, participant
compliance was monitored by having participants return
empty packets of their supplement during post-testing
(week 4). Compliance to the supplementation protocol
was greater than 90% for all subjects.
Resistance Training Protocol
To get an accurate representation of current physical
activity habits, all participants were asked and monitored
to follow a 4-day split-body resistance training program [5].
The workout, which consisted of 12 exercises, involved
upper and lower body training twice per week using a 4-
day split (i.e., upper body on Monday, lower body on
Tuesday, upper body on Thursday, lower body on Friday),
increasing gradually in intensity and volume. Lower body
exercises included leg extension, leg curl, barbell or Smith-
machine squat, lunge, dead lift, and calf raise. Upper body
exercises included the lat pull down, seated row, triceps
press down, bench press, shoulder press, and dips. For the
first 2 weeks, participants completed four sets of 12 to 15
repetitions at intensities equivalent to 10- to 12-repetition
maximum loads. For the final 2 weeks, participants
completed four sets of six to eight repetitions at intensities
equivalent to a six- to eight-repetition maximum load.
Participants rested for 2 min between each set of exercise
and 2 min between each exercise. Training was documented
in training logs and signed off by fitness instructors and/or
gym personnel at the patient's local training facility.
Statistical Analysis
All data were first tested for normality by the Shapiro–Wilk
test and standardized skewness and kurtosis z scores. If
normality was violated, data were log transformed. Homog-
enous baseline samples were determined by using an
independent samples t test on all descriptive data (age,
height, weight) and body mass index variables. If baseline
differences were found, data were analyzed using ANCOVA
statistics with that baseline variable as a covariate. Separate 2
(group)×2 (time) mixed factorial analysis of variance with
repeated measures on test to determine main and interactive
effects with Bonferroni corrections applied to all confidence
intervals was used for all dependent variables. When
interactive effects were found, simple pairwise comparisons
were used to identify all differences. A significance value of
0.05 was applied for all statistical decisions. No data sets
from dropouts were included in the statistical analyses.
Results
Baseline Values
Baseline values for all participants were computed and
compared to ensure homogeneity of the groups. As
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indicated in Table 1, no significant (p>0.05) baseline
differences were reported in criterion variables with the
exception of resting diastolic blood pressure (group A=
78.9±7.9 vs. group B=71.8±7.9 mmHg; p<0.05), alanine
aminotransferase (ALT) (group A=35.7±26.5 vs. group B=
20.3±7.7; p<0.05), and fasting glucose (group A=5.0±
0.4 mmol L−¹ vs. group B=4.7±0.3; p<0.01).
Dietary Intake
Absolute (kilocalories per day) and relative (kilocalories per
kilogram per day) average energy intake per person changed
from 2,662 kcals d−¹ at baseline (T0) to 2,597 kcals d−¹ at the
end of the 4-week protocol (T1), p=0.047. This reduction
was estimated to be 65 kcals d−¹. Average carbohydrate
intake changed from 3.3±1.0 g CHO kg d−¹ at T0 to 3.2±
0.97 g CHO kg d−¹ at T1 (p<0.05). Average daily protein
intake changed from 2.9±0.99 g PRO kg d−¹ at T0 to 3.1±
1.01 g PRO kg d−¹ at T1 (p<0.001). No significant (p=0.05)
interactive effects, group (G)×time (T), were found for
relative carbohydrate and protein intake. Average fat intake
changed from 0.9±0.35 g fat kg d−¹ at T0 to 0.85±0.35 g
fat kg d−¹. A significant (p=0.05) interaction was found for
fat intake normalized to body mass in kilograms as the
relative fat intake remained constant in group B and was 11%
lower in group A at T1 (p=0.044).
Adverse Events and Compliance
Adverse event forms were provided by the clinical research
facility. Participants were required to submit adverse event
reports at the conclusion of the study or upon withdrawal of
the study for any reason. Some episodes of upset stomach,
nausea, and headache were reported to the study dietitian
from both groups but none serious enough to require
dropping out of the study. No adverse event forms were
submitted from supplementation was reported from either
group. Compliance to the supplementation protocol was
reported to be greater than 90% as indicated by returned
packets and weekly follow-up by the fitness staff. Similarly,
compliance to the resistance protocol was recorded by
fitness staff and was reported to be greater than 90% as four
participants reported missing no more than two workouts.
Two subjects in group B did not finish due to injury and
illness. Two others in group B were eliminated due to
incomplete data sets.
Markers of Metabolic and Cardiovascular Health
No significant (p>0.05) main or interactive effects (G×T)
were reported for resting heart rate, systolic blood pressure,
and diastolic blood pressure. Although an interactive effect
for diastolic blood pressure began to approach significance
(G×T; p=0.06), all values for both groups A and B reported
diastolic blood pressure values in normally expected ranges
(Table 2). No significant (p=0.05) changes were reported
for serum levels of HDL cholesterol, triglycerides, and
glucose and the ratio of total and HDL cholesterol. A
significant (p=0.05) interactive effect was found for serum
total cholesterol values. Table 2 shows serum levels did not
change for group Awhile a significant (p=0.05) increase in
total cholesterol values was reported in group B (whey
protein only). Similar findings were also reported for LDL
cholesterol as serum changes in group A were not
significant (p=0.05), but LDL cholesterol values in group
B increased significantly (p=0.05).
Other Serum Clinical Markers
No significant (p>0.05) interactive effects were found for
the following variables: sodium (G×T; p=0.87), chloride
(G×T; p=0.82), carbon dioxide (G×T; p=0.84), bilirubin
(G×T; p=0.91), albumin (G×T; p=0.59), globulin (G×T;
p=0.61), albumin/globulin (G×T; p=0.70), glomerular
filtration rate (G×T; p=0.38), alkaline phosphatase (G×
T; p=0.44), AST (G×T; p=0.23), blood urea nitrogen (G×
T; p=0.19), and total protein (G×T; p=0.51). Main effects
for time but no significant (p=0.05) G×T interaction
effects were found for creatinine, BUN/creatinine, and
albumin. All values, however, remained within expected
clinical norms. Significant (p=0.05) G×T interaction
effects were found for serum potassium and calcium
(Table 3). All effects were found to remain within
expected clinical values.
Discussion
The purpose of this study was to evaluate parameters of
general physical health, metabolic function, cardiovascular
health, and hepato-renal function when adding a specific
fungal protease enzyme system to twice daily (80 g per day
total) whey protein supplementation in healthy, active
participants maintaining a regimen of resistance training.
A number of previous reports have suggested that in an
independent fashion, supplementation with whey protein
[6–9] and fungal proteases [10, 11] may confer favorable
health outcomes. It was initially hypothesized that the
fungal protease addition to whey protein would favorably
impact cardiovascular responses without instigating any
unfavorable changes in glucose and lipid panels as well as
markers of kidney, liver, and general metabolic function.
The primary findings from this study demonstrate that 40-g
doses of whey protein, twice a day, containing 3% Amino-
gen® are well tolerated as none of the parameters evaluated
including the clinical chemistry profiles were negatively
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affected. This is also supported by no adverse events being
reported throughout the 4-week study period.
There were surprising findings regarding significant
main and interactive effects reported for total cholesterol
and LDL cholesterol (Table 2). Similarly, interactive effects
for diastolic blood pressure strongly approached signifi-
cance (p=0.06) and are worth discussing (Table 2).
Interestingly, for all of these variables, significant increases
were shown to occur or were very close to being significant
(diastolic blood pressure; p=0.06) for only group B, the
whey protein group, while no such changes were seen in
group A, the Aminogen®+whey protein group. Careful
interpretation of these findings is suggested, however, due
to the fact that all significant changes still resulted in values
which remained within clinically accepted ranges (Table 2).
This change could be partially explained by a significant
increase in dietary fat, but this was not reported in either
group. Consumption of fat significantly (p=0.05) decreased
Table 2 Metabolic and
cardiovascular health marker
changes for the Aminogen®+
whey protein (group A) and
whey protein (group B) subject
groups
All data are presented as group
means ± standard deviation for
week 0 (T0) and week 4 (T1) of
the protocol. Individual main
effects for time are provided as
within-group p values. Group×
time interaction effects are pro-
vided as G×T p values.
Between-group significance
indicators represent the change
from T0 to T1. Significance
level was 0.05
aDifferent from baseline
bDifferent than group A
Variable Group T0 T1 p value
Week 0 Week 4 Within group Time G×T
Resting HR (bpm) A 69.8±10.0 69.2±7.4 0.74 0.62 0.97
B 69.1±8.7 68.4±10.6 0.71
Systolic BP (mmHg) A 124±11.5 126±10.6 0.33 0.07 0.67
B 118±11.3 122±11.0 0.83
Diastolic BP (mmHg) A 78.9±7.9 77.5±8.9 0.34 0.59 0.06
B 71.8±7.9 74.1±7.9 0.06
Total cholesterol (mmol L−1) A 4.1±0.8 4.1±1.0 0.76 0.09 <0.05
B 3.7±0.9 4.1±0.8ab <0.05
LDL cholesterol (mmol L−1) A 2.51±0.82 2.46±0.94 0.74 0.12 0.05
B 2.10±0.81 2.53±0.94ab <0.05
HDL cholesterol (mmol−1) A 1.22±0.41 1.20±0.39 0.55 0.20 0.29
B 1.39±0.69 1.20±0.37 0.29
Total Chol/HDL A 5.1±7.7 4.5±5.2 0.36 0.49 0.11
B 3.0±1.0 4.4±4.2 0.22
Triglycerides (mmol L−1) A 0.90±0.45 0.95±0.46 0.49 0.35 0.91
B 0.76±0.20 0.80±0.23 0.51
Glucose (mmol L−1) A 5.02±0.36 4.84±0.58 0.18 0.32 0.28
B 4.70±0.28 4.70±0.40 0.95
Table 3 Selected clinical
markers of safety for the
Aminogen®+whey protein
(group A) and whey protein
(group B) subject groups
All data are presented as group
means ± standard deviation for
week 0 (T0) and week 4 (T1) of
the protocol. Individual main
effects for time are provided as
within-group p values. Group×
time interaction effects are pro-
vided as G×T p values.
Between-group significance
indicators represent the change
from T0 to T1. Significance
level was 0.05 [13]
aDifferent from baseline
bDifferent than group B
Variable Group Week 0 Week 4 p value
Within group Time G×T
Potassium (U L−1) A 4.33±0.33 4.25±0.24 0.23 0.57 0.05
B 4.19±0.22 4.34±0.30 0.15
Calcium A 9.6±0.24 9.5±0.22 0.62 0.07 <0.05
B 9.4±0.31 9.6±0.25ab <0.05
Alkaline phosphatase (U L−1) A 71.3±15.8 71.3±18.9 0.24 0.46 0.44
B 66.3±14.0 64.3±17.3 0.08
AST (U L−1) A 33.1±22.1 27.2±19.0 0.08 0.08 0.23
B 23.6±8.1 22.3±5.8 0.48
ALT (U L−1) A 35.7±26.5 32.7±25.4 0.16 0.78 0.07
B 20.3±7.7 22.6±9.3 0.23
BUN (mg dL−1) A 17.7±4.92 19.3±5.4 0.07 0.26 0.19
B 17.6±0.98 17.5±3.7 0.90
Creatinine (mg dL−1) A 2.32±5.2 2.28±5.2ab <0.001 <0.005 0.60
B 1.15±0.17 1.10±0.14 0.65
BUN/creatinine A 15.1±3.7 17.2±4.6 0.20 <0.05 0.15
B 15.4±2.8 15.8±3.1 0.65
Total protein (U L−¹) A 7.1±0.42 7.2±0.42 0.63 0.17 0.51
B 7.0±0.36 7.1±0.36 0.13
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over time in group A; however, total cholesterol and LDL
cholesterol levels reportedly did not change. It is notewor-
thy that the addition of whey protein to the diet may have
increased dietary fat as well as blood levels of cholesterol
and LDL, but this change was made to both experimental
groups. An increase in cholesterol after supplementing with
whey protein has not been indicated in healthy persons [5,
7, 12]. In fact, studies in metabolically challenged pop-
ulations (e.g., overweight or hypertensive participants) have
shown that whey protein supplementation may help to
lower cholesterol [6, 9]. It may be speculated that the
proteases in Aminogen® may interact with whey protein to
produce a greater cholesterol-lowering effect than whey
protein alone, possibly through the production of bioactive
peptides. Oben [4] reported significant decreases in C-
reactive protein in a test group after an acute consumption
of 5% and 10% Aminogen® blended with whey protein.
Additionally, unpublished in vitro data have shown that
Aminogen® hydrolyzes whey, soy, and casein proteins to
produce peptides that inhibit angiotensin-converting en-
zyme, a mechanistic finding which may help to explain the
divergent responses to diastolic blood pressure. These
results suggest the possibility that the protease enzymes in
Aminogen® may be producing bioactive peptides from
whey protein that are not produced by endogenous protease
enzymes. These peptides may help facilitate lower blood
levels of total cholesterol and LDL cholesterol than
peptides produced from whey protein by endogenous
proteases leading to greater cardiovascular effects. Further
studies may help to explain the significance of increased
blood levels of total cholesterol and LDL cholesterol as
well as increased diastolic blood pressure in the whey
protein only group reported in this study. A more
significant finding, however, may be that, as hypothesized,
whey protein containing 3% Aminogen® was well tolerated
by subjects and results in no significant changes in hemody-
namic parameters or markers of clinical safety for cardiovas-
cular, calcium, liver, and kidney function when compared to
whey protein alone. These findings are significant because of
the lack of existing safety data on fungal enzymes when used
as dietary supplements.While fungal enzymes have been used
for many years in food processing and as food additives, the
use of active fungal enzymes as dietary supplements is
currently unregulated in many countries including the
European Union member countries and Canada. This is
primarily due to the lack of published clinical safety data.
This study may help support the safety of repeated use of the
fungal proteases in Aminogen® as a dietary supplement.
In conclusion, these results indicate that twice daily
supplementation of 40 g whey protein containing 3% of the
active fungal protease enzyme system Aminogen® was well
tolerated during this 4-week study. The addition of Amino-
gen® to whey protein resulted in no adverse events and did
not cause any measurable negative changes in various
markers of clinical health. These, as well as previous results
[4], support the safety and potential benefits of ingesting
Aminogen® with an appropriate substrate such as whey
protein. They also indicate further research regarding the
combination of Aminogen® with protein-based foods and
beverages is warranted.
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